Abstract
Several advances in molecular genetics and cardiac imaging of patients with hypertrophic cardiomyopathy (HCM) have been developed in recent years. The commercially available genetic testing is currently used (a) to identify affected relatives in families known to have HCM and (b) to differentiate HCM from metabolic storage disorders and other HCM phenocopies. Cardiovascular magnetic resonance has emerged as a useful tool to assess the magnitude and distribution of hypertrophy or mitral valve apparatus anatomy, which may have an impact on decision making regarding invasive management of HCM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
